title: Preterm infants with or developing chronic lung disease (CLD)
text: |
  Preterm infants with or developing chronic lung disease (CLD)
  |
  bet | 228/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Preterm infants with or developing chronic lung disease (CLD): In preterm infants < 3 weeks of age developing CLD, furosemide administration has either inconsistent effects or no detectable effect. In infants > 3 weeks of age with CLD, a single intravenous dose of 1 mg/kg of furosemide improves lung compliance and airway resistance for one hour. Chronic administration of furosemide improves both oxygenation and lung compliance. Routine or sustained use of systemic loop diuretics in infants with (or developing) CLD cannot be recommended based on current evidence.3 (LOE II, GOR C)
  Aerosolised diuretics for preterm infants with (or developing) chronic lung disease: In preterm infants > 3 weeks with CLD, administration of a single dose of aerosolised furosemide improves pulmonary mechanics. In view of the lack of data from randomised trials concerning effects on important clinical outcomes, routine or sustained use of aerosolised loop diuretics in infants with (or developing) CLD cannot be recommended based on current evidence.4 (LOE I GOR C)
  |
  | |